NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing (the “Offering”), previously announced on November 6, 2025, to $858,000 and the closing of the fourth and final tranche (the “Fourth Tranche”). Gross p

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly selective and pot

WEDNESDAY, Dec. 31, 2025 — Does it sometimes feel like your supper is sitting like a boulder in your gut? You may have a condition called gastroparesis. About 1 in 4 people have symptoms of the disorder, which causes the stomach to empty slowly, according to the National Institutes of Health. “Patients don’t come in telling you they have a gastric delay,” Dr. Braden Kuo , chief of gastroenterology at Columbia University and New York Presbyterian, told NIH News in Health . Feeling full quickly,

Dec 31, 2025 —Laekna, Inc. (2105.HK) today announced that the company has commenced study recruitment in phase I single ascending dose study (the “SAD study”) of LAE103, an internally discovered monoclonal antibody against ActRIIB in Australia. As of the date of this announcement, first subject has been dosed. The SAD study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in

WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and management of this debilitating physiologic r

Thanks to the quick action and expertise of Baystate's Heart and Vascular team, Abby Labonte survived a massive heart attack, received a new heart, and came back to say thank you SPRINGFIELD, Mass., Dec. 30, 2025 /PRNewswire/ -- As Valentine's Day approached in 2025, Abigael "Abby" LaBonte, of Easthampton, Mass., added a small heart to her usual manicure, as a cheerful way to celebrate the holiday. At this point, she had no idea how meaningful that little heart would soon be. On February 14, Abb

ٍRIYADH, SAUDI ARABIA, December 30, 2025 / EINPresswire.com / -- At King Faisal Specialist Hospital & Research Centre (KFSHRC), patient safety is closely linked to the hospital’s ability to reach accurate diagnoses when standard clinical tools fall short. This is particularly critical in cases of severe or unexplained infections, where delays in identification can affect treatment decisions and outcomes. To address this challenge, KFSHRC has developed a metagenomic diagnostic protocol that appli

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo Nordisk's Ozempic or Wegovy. PORT WASHINGTON, N.Y., Dec. 30, 2025 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits in on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. Most recently, on December 24, 202

A family case narrative and recent research highlight how EEG-guided rTMS is being studied in autism research. WIMBERLEY, TX, UNITED STATES, December 30, 2025 / EINPresswire.com / -- Brain Treatment USA has released an expanded case narrative and research summary to help clarify how repetitive transcranial magnetic stimulation (rTMS) and EEG-guided rTMS (also referred to as MeRT or Magnetic e-Resonance Therapy) approaches are being evaluated in autism research. The update comes amid growing publ

CAMBRIDGE, Mass., Dec. 30, 2025 /PRNewswire/ -- NGD Infection Prevention, a global provider of real-time genomic transmission detection for hospitals, has deployed an integrated transmission detection system to Sheba Medical Center in Ramat Gan, Israel. Sheba, the largest medical center in the Middle East and ranked among the top 10 hospitals in the world, will be the first hospital in Israel to implement NGD's sequencing-based system to detect and prevent outbreaks as they start. Deployment to